Vital Chemtech Ltd (VITAL)

Chemicals · Chemicals · NSE · Updated 1 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

🎯 Key Takeaways

Vital Chemtech Ltd appears to be in a transitional phase marked by financial stabilization after prior losses, with management focusing on operational consolidation and compliance. The company has returned to profitability in recent quarters following strategic investments, though margins remain thin and growth is uneven.
Revenue grew 45.7% QoQ to ₹51 in Q1FY27.
⚠️ Margins remain highly volatile and sensitive to subsidiary investments, with PAT margin at 0.8% in FY26 despite improvement in EBITDA trends.

ROE

3.3%

ROCE

5.8%

Debt/Equity

0.52

Promoter

73.4%

✨ Ask AI About VITAL 📊 Interactive Charts

📖 The Story

Vital Chemtech Ltd appears to be in a transitional phase marked by financial stabilization after prior losses, with management focusing on operational consolidation and compliance. The company has returned to profitability in recent quarters following strategic investments, though margins remain thin and growth is uneven. It operates with a conservative capital structure but shows limited reinvestment momentum, suggesting a mature or stabilization phase rather than aggressive expansion.

📰 What's Happening

In Q1 FY27, the company reported revenue of ₹51 crores with operating profit of ₹4 crores and net profit of ₹3 crores, marking a significant turnaround from losses in Q4 FY26. Management highlighted stable performance amid strategic investments in subsidiaries, with Q4 FY26 showing 39.7% YoY EBITDA growth to ₹4 crores despite revenue stability. The Board approved audited consolidated results for FY26 on May 29, 2026, and appointed R J & Associates as cost auditor for FY27. No promoter share acquisitions or encumbrances occurred during FY26, reinforcing governance transparency. The trading window for insider transactions closed 48 hours after the Q1 FY27 results release, in compliance with SEBI regulations.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Mar 2025	Jun 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	35	34	27	35	51
Operating Profit	2	1	-0	2	4
OPM %	4.5%	4.2%	-1.2%	5.5%	8.4%
Net Profit	1	1	-1	1	3
EPS	₹0.49	₹0.41	₹-0.55	₹0.36	₹1.08

The company swung from a loss of ₹1 crore in Q4 FY26 to a profit of ₹3 crores in Q1 FY27, with EBITDA margin expanding to 8.4% from negative levels just two quarters prior. This improvement follows strategic investments in subsidiaries that initially compressed margins but are now yielding operational stability. Revenue in Q1 FY27 (₹51 crores) is up from ₹35 crores in Q4 FY26, indicating early signs of recovery after a period of margin pressure and investment-led disruption. The trend suggests management’s capital allocation is beginning to stabilize, though profitability remains sensitive to execution.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the reviewed filings, but the consistent approval of financial results, auditor confirmations, and regulatory compliance updates indicate a focus on transparency and operational discipline. The appointment of auditors and adherence to SEBI LODR and Ind AS reflect a commitment to governance. No strategic initiatives or growth targets were disclosed in the latest board meeting minutes or general filings, suggesting a cautious, compliance-driven approach rather than an expansionary narrative.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2026	Mar 2026
Equity Capital	24	24	24
Reserves	68	69	75
Borrowings	48	66	62
Total Liabilities	182	161	219
Fixed Assets	68	93	58
Investments	20	14	13
Total Assets	182	161	219

The balance sheet shows stable equity of ₹24 crores and reserves increasing from ₹68 to ₹75 crores between March 2025 and March 2026, while total assets rose to ₹219 crores. Borrowings increased slightly to ₹62 crores from ₹48 crores, suggesting modest leverage growth. Despite asset expansion, equity remains flat, indicating limited internal capital generation or dividend payouts. The capital structure remains conservative with low D/E of 0.52, but the lack of significant deleveraging or reinvestment signals suggests limited confidence in high-return organic opportunities.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+6
Investing	-30
Financing	+25
Net Cash Flow	+0

👥 Shareholding Pattern

Category	Q4FY25	Q2FY26	Q4FY26	Q1FY27
Promoters	73.4%	73.4%	73.4%	73.4%
FII	1.8%	1.8%	1.6%	1.6%
DII	0.0%	0.0%	0.3%	0.3%
Public	20.8%	20.8%	21.1%	20.9%
# Shareholders	2,142	2,092	2,023	2,098

Promoter holding remains stable at 73.43% across all recent quarters, with no encumbrances or share acquisitions reported under SEBI takeover regulations. FII holdings have slightly declined from 1.78% in Q2 FY26 to 1.62% in Q1 FY27, while DII remains minimal at 0.25%. The number of public shareholders has decreased slightly, but overall shareholding pattern shows no signs of institutional accumulation or exit pressure. Governance disclosures emphasize stability and transparency, with no activist or strategic investor activity noted.

⚖️ Peer Comparison — Chemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
PIDILITIND	1.67 L Cr	63.2	33.4%	24.7%	0.01
SRF	75,831	35.1	15.6%	15.4%	0.36
LINDEINDIA	54,443	99.7	17.5%	12.8%	0.00
FLUOROCHEM	51,528	84.2	9.6%	7.7%	0.34
NAVINFLUOR	44,502	56.3	22.2%	19.9%	0.31
GODREJIND	38,256	32.5	9.2%	19.8%	4.57
HSCL	33,181	41.2	20.7%	17.1%	0.16
DEEPAKNTR	23,850	30.4	15.3%	13.4%	0.26
AETHER	22,459	95.2	13.8%	10.6%	0.08
AARTIIND	19,021	35.8	9.2%	9.5%	0.68

🔗 Peer Stock Analyses

PIDILITIND SRF LINDEINDIA FLUOROCHEM NAVINFLUOR

⚠️ Risk Factors

1. Margins remain highly volatile and sensitive to subsidiary investments, with PAT margin at 0.8% in FY26 despite improvement in EBITDA trends. 2. Reliance on a few subsidiary investments for profitability introduces execution and integration risks. 3. Low and stable institutional interest (FII/DII < 2%) suggests limited investor confidence or liquidity. 4. Flat equity base amid asset growth raises questions about capital efficiency and potential over-leverage in a low-return environment.

📋 Recent Filings

🧠 Analyst's Read

Vital Chemtech is transitioning from a loss-making trajectory to operational stability, driven by strategic investments now yielding modest returns. The key watchpoint is whether margin recovery sustains without further capital dilution or investment cycles. With promoter control intact and no governance red flags, the company presents a low-drama profile, but upside is capped by thin margins and minimal reinvestment signals. Investors should monitor next quarter’s EBITDA and margin trends for confirmation of sustainable recovery.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VITAL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VITAL files new disclosures

Track VITAL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VITAL — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd